<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Enzolytics Inc — News on 6ix</title>
<link>https://6ix.com/company/enzolytics-inc</link>
<description>Latest news and press releases for Enzolytics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 22 Sep 2025 14:03:52 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/enzolytics-inc" rel="self" type="application/rss+xml" />
<item>
<title>ENZC Receives Letter of Support</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzc-receives-letter-of-support</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzc-receives-letter-of-support</guid>
<pubDate>Mon, 22 Sep 2025 14:03:52 GMT</pubDate>
<description>ENZC Receives Letter of Support.</description>
</item>
<item>
<title>Enzolytics announces New Ceo and 500 to 1 Reverse Split</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-announces-new-ceo-and-500-to-1-reverse-split</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-announces-new-ceo-and-500-to-1-reverse-split</guid>
<pubDate>Wed, 04 Jun 2025 16:56:59 GMT</pubDate>
<description>Enzolytics announces New Ceo and 500 to 1 Reverse Split.</description>
</item>
<item>
<title>ENZOLYTICS REFUTES CLAIMS</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-refutes-claims</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-refutes-claims</guid>
<pubDate>Wed, 04 Jun 2025 13:37:10 GMT</pubDate>
<description>ENZOLYTICS REFUTES CLAIMS.</description>
</item>
<item>
<title>Creatd, Inc. (OTC: CRTD) Completes Initial Stock Swap with Enzolytics, Inc. (OTC: ENZC) in Strategic Transaction</title>
<link>https://6ix.com/company/enzolytics-inc/news/creatd-inc-otc-crtd-completes-initial-stock-swap-with-enzolytics-inc-otc-enzc-in-strategic-transaction-1</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/creatd-inc-otc-crtd-completes-initial-stock-swap-with-enzolytics-inc-otc-enzc-in-strategic-transaction-1</guid>
<pubDate>Fri, 24 Jan 2025 14:30:00 GMT</pubDate>
<description>Creatd, Inc. (OTC: CRTD) Completes Initial Stock Swap with Enzolytics, Inc. (OTC: ENZC) in Strategic Transaction.</description>
</item>
<item>
<title>ENZOLYTICS, INC. ANNOUNCES IMPLEMENTATION OF CAPITAL RESTRUCTURING PLAN AS PART OF ONGOING ACQUISITION STRATEGY OFFERS UPDATE ON SAGALIAM ACQUISITION CORP</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-implementation-of-capital-restructuring-plan-as-part-of-ongoing-acquisition-strategy-offers-update-on-sagaliam-acquisition-corp</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-implementation-of-capital-restructuring-plan-as-part-of-ongoing-acquisition-strategy-offers-update-on-sagaliam-acquisition-corp</guid>
<pubDate>Wed, 06 Nov 2024 13:13:58 GMT</pubDate>
<description>ENZOLYTICS, INC. ANNOUNCES IMPLEMENTATION OF CAPITAL RESTRUCTURING PLAN AS PART OF ONGOING ACQUISITION STRATEGY OFFERS UPDATE ON SAGALIAM ACQUISITION CORP.</description>
</item>
<item>
<title>Enzolytics, Inc. Addresses Additional Misinformation</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-addresses-additional-misinformation</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-addresses-additional-misinformation</guid>
<pubDate>Thu, 24 Oct 2024 14:16:20 GMT</pubDate>
<description>Enzolytics, Inc. Addresses Additional Misinformation.</description>
</item>
<item>
<title>Enzolytics Inc. Response to Competitor’s Continuing False and Misleading Statements Regarding Zhabilov Trust Patents Statements were Included in NIKA Pharmaceuticals June 30, 2024 10-Q filed with SEC</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-response-to-competitors-continuing-false-and-misleading-statements-regarding-zhabilov-trust-patents-statements-were-included-in-nika-pharmaceuticals-june-30-2024-10-q-filed-with-sec</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-response-to-competitors-continuing-false-and-misleading-statements-regarding-zhabilov-trust-patents-statements-were-included-in-nika-pharmaceuticals-june-30-2024-10-q-filed-with-sec</guid>
<pubDate>Mon, 14 Oct 2024 13:32:56 GMT</pubDate>
<description>Enzolytics Inc. Response to Competitor’s Continuing False and Misleading Statements Regarding Zhabilov Trust Patents Statements were Included in NIKA Pharmaceuticals June 30, 2024 10-Q filed with SEC.</description>
</item>
<item>
<title>ENZOLYTICS, INC. AND DEPARTMENT OF IMMUNOLOGY, INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES BEGINS PROJECT FOCUSING ON DEVELOPMENT OF MELANOMA VACCINE</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-and-department-of-immunology-institute-of-microbiology-bulgarian-academy-of-sciences-begins-project-focusing-on-development-of-melanoma-vaccine</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-and-department-of-immunology-institute-of-microbiology-bulgarian-academy-of-sciences-begins-project-focusing-on-development-of-melanoma-vaccine</guid>
<pubDate>Tue, 08 Oct 2024 00:53:23 GMT</pubDate>
<description>ENZOLYTICS, INC. AND DEPARTMENT OF IMMUNOLOGY, INSTITUTE OF MICROBIOLOGY, BULGARIAN ACADEMY OF SCIENCES BEGINS PROJECT FOCUSING ON DEVELOPMENT OF MELANOMA VACCINE.</description>
</item>
<item>
<title>Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator</title>
<link>https://6ix.com/company/enzolytics-inc/news/bulgarian-academy-of-sciences-issues-report-on-results-of-its-in-vivo-testing-of-ipf-as-an-immunomodulator</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/bulgarian-academy-of-sciences-issues-report-on-results-of-its-in-vivo-testing-of-ipf-as-an-immunomodulator</guid>
<pubDate>Wed, 18 Sep 2024 14:19:55 GMT</pubDate>
<description>Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator.</description>
</item>
<item>
<title>Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement </title>
<link>https://6ix.com/company/enzolytics-inc/news/department-of-immunology-institute-of-microbiology-bulgarian-academy-of-sciences-and-enzolytics-inc-execute-three-year-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/department-of-immunology-institute-of-microbiology-bulgarian-academy-of-sciences-and-enzolytics-inc-execute-three-year-agreement</guid>
<pubDate>Mon, 09 Sep 2024 14:02:59 GMT</pubDate>
<description>Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement.</description>
</item>
<item>
<title>Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells</title>
<link>https://6ix.com/company/enzolytics-inc/news/final-report-from-the-national-centre-of-infectious-and-parasitic-diseases-concludes-lyophilized-pepsin-significantly-reduces-the-survival-and-proliferation-of-growth-in-specific-cancer-cells</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/final-report-from-the-national-centre-of-infectious-and-parasitic-diseases-concludes-lyophilized-pepsin-significantly-reduces-the-survival-and-proliferation-of-growth-in-specific-cancer-cells</guid>
<pubDate>Tue, 20 Aug 2024 13:16:59 GMT</pubDate>
<description>Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells.</description>
</item>
<item>
<title>Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications </title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-and-the-bulgarian-academy-of-sciences-initiate-a-cooperative-program-primarily-focusing-on-applied-and-strategic-research-in-immunology-for-cancer-and-hivaids-applications</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-and-the-bulgarian-academy-of-sciences-initiate-a-cooperative-program-primarily-focusing-on-applied-and-strategic-research-in-immunology-for-cancer-and-hivaids-applications</guid>
<pubDate>Wed, 31 Jul 2024 16:13:48 GMT</pubDate>
<description>Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications.</description>
</item>
<item>
<title>Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-enters-into-collaboration-agreement-with-manufacturer-elimus-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-enters-into-collaboration-agreement-with-manufacturer-elimus-ltd</guid>
<pubDate>Mon, 29 Jul 2024 13:51:59 GMT</pubDate>
<description>Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd..</description>
</item>
<item>
<title>Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-supports-sagaliam-acquisition-corp-response-to-competitors-false-and-misleading-press-release</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-supports-sagaliam-acquisition-corp-response-to-competitors-false-and-misleading-press-release</guid>
<pubDate>Fri, 26 Jul 2024 20:30:57 GMT</pubDate>
<description>Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release.</description>
</item>
<item>
<title>SAGALIUM RESPONDS TO COMPETITOR’S FALSE AND MISLEADING PRESS RELEASE</title>
<link>https://6ix.com/company/enzolytics-inc/news/sagalium-responds-to-competitors-false-and-misleading-press-release</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/sagalium-responds-to-competitors-false-and-misleading-press-release</guid>
<pubDate>Thu, 25 Jul 2024 20:46:06 GMT</pubDate>
<description>SAGALIUM RESPONDS TO COMPETITOR’S FALSE AND MISLEADING PRESS RELEASE.</description>
</item>
<item>
<title>Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-enters-into-exclusive-worldwide-license-for-patented-immunotherapy-cancer-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-enters-into-exclusive-worldwide-license-for-patented-immunotherapy-cancer-treatment</guid>
<pubDate>Mon, 01 Jul 2024 13:37:05 GMT</pubDate>
<description>Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment.</description>
</item>
<item>
<title>Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-poised-to-invest-alongside-sagaliam-acquisition-corp-in-revolutionary-room-temperature-spad-technology</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-poised-to-invest-alongside-sagaliam-acquisition-corp-in-revolutionary-room-temperature-spad-technology</guid>
<pubDate>Mon, 03 Jun 2024 12:47:17 GMT</pubDate>
<description>Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology.</description>
</item>
<item>
<title>Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-letter-of-intent-for-exclusive-licensing-agreement-for-patented-nitric-oxide-formulation</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-letter-of-intent-for-exclusive-licensing-agreement-for-patented-nitric-oxide-formulation</guid>
<pubDate>Wed, 22 May 2024 14:31:08 GMT</pubDate>
<description>Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation.</description>
</item>
<item>
<title>ENZOLYTICS, INC. ANNOUNCES LETTER OF INTENT FOR EXCLUSIVE LICENSING AGREEMENT FOR PATENTED NITRIC OXIDE FORMULATION</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-letter-of-intent-for-exclusive-licensing-agreement-for-patented-nitric-oxide-formulation-1</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-letter-of-intent-for-exclusive-licensing-agreement-for-patented-nitric-oxide-formulation-1</guid>
<pubDate>Wed, 22 May 2024 14:02:11 GMT</pubDate>
<description>ENZOLYTICS, INC. ANNOUNCES LETTER OF INTENT FOR EXCLUSIVE LICENSING AGREEMENT FOR PATENTED NITRIC OXIDE FORMULATION.</description>
</item>
<item>
<title>Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment</title>
<link>https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-formation-of-marketing-company-in-partnership-with-third-coast-fulfillment</link>
<guid isPermaLink="true">https://6ix.com/company/enzolytics-inc/news/enzolytics-inc-announces-formation-of-marketing-company-in-partnership-with-third-coast-fulfillment</guid>
<pubDate>Thu, 02 May 2024 13:51:47 GMT</pubDate>
<description>Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment.</description>
</item>
</channel>
</rss>